ClinicalTrials.gg
CompletedNCT05924243Updated Sep 19, 2024

A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease.

A Phase 1 interventional study of RO7486967 and Placebo in Parkinson Disease, sponsored by Hoffmann-La Roche. Completed at 17 sites in 3 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 3 months ago, and no results have been posted to the registry.
  • Registered 8 months after the study started (first participant enrolled Sep 2022, registered Jun 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.

Enrollment
418th of 1,256
60 · median 36
Started
2022
with 104 others
Phase 1
175 of 1,649
32 open now
Registered
1,370th of 1,649
by date

Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 418th largest by enrollment of the 1,256 interventional ones that give a count, is one of 105 that started in 2022, is one of 175 in phase 1, and was the 1,370th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

299 more — sign in →

All 304 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,649 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double blind, adaptive, parallel-group, placebo controlled Phase 1b study to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamics of RO7486967 in participants with idiopathic PD at the early stage of the disease (modified H\&Y stage ≤2.5) who are either treatment-naïve or on stable treatment with symptomatic therapy (levodopa and/or pramipexole, ropinirole, rotigotine).

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Diagnosis of clinically probable idiopathic PD based on MDS criteria with bradykinesia plus one of the other cardinal signs of PD (resting tremor, rigidity)
  • A time from diagnosis of PD of at least 3 to maximum 60 months (5 years) at screening
  • Modified H\&Y Stage ≤2.5 (in ON state)
  • Dopaminergic imaging consistent with dopamine transporter deficit
  • "High-affinity binder" or "mixed-affinity binder" genotype for TSPO
  • Either treatment naïve or treatment with symptomatic PD therapy (levodopa and/or pramipexole, ropinirole, rotigotine) given for at least 90 days, with stable doses for at least 30 days prior to the first dose
  • No anticipated changes in PD therapy throughout the study duration
  • SARS-CoV-2 vaccination completed at least 60 days prior to the first dose.

Exclusion criteria

Exclusion Key Criteria:

  • Medical history indicating a Parkinsonian syndrome other than idiopathic PD
  • CNS or psychiatric disorders other than idiopathic PD (mild depression or anxiety arising in the context of PD is not exclusionary)
  • History of brain surgery for PD
  • Use of any of symptomatic drug for PD other than levodopa pramipexole, ropinirole, or rotigotine within 60 days prior to the first dose
  • Known carriers for mutations in the following genes: alpha-synuclein, LRRK2, GBA, PRKN, PINK1, or DJ1
  • Unstable or cardiovascular disease within the last year prior to screening
  • Uncontrolled hypertension
  • Use of oral anticoagulants, low-molecular-weight heparin, warfarin (Coumadin), acenocoumarol, and phenprocoumon is not allowed within 10 days before the first Lumbar Puncture and during the study (low dose aspirin is permitted as monotherapy)
  • Concomitant disease or unstable medical condition within 6 months of screening that could interfere with the study or treatment that might interfere with the conduct of the study, including but not limited to disease, immunodeficiency diseases, any active infectious disease
  • History of immunodeficiency diseases
  • Presence of surface antigen (HBsAg) or positive for total hepatitis B core antibody (HBcAb), or positive (HCV) at screening
  • Vaccine(s) other than SARS-CoV2 vaccine within 28 days prior to the first dose, or plans to receive vaccines during the study or within 28 days of the last dose
  • History of chronic liver disease
  • Clinically significant abnormalities in laboratory test results at screening, including hepatic and renal panels, complete blood count, chemistry panel and urinalysis
  • Any previous administration of RO7486967 or other compound targeting NLRP3
  • Enrollment in another study
  • Use of any of other investigational therapy (other than protocol-mandated study treatment) within 90 days or 5 drug elimination half-lives (whichever is longer) prior to the first dose
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    RO7486967 Arm

    Participants will receive RO07486967 for approximately 28 days with 14 days of follow up after the last dose.

    Drug: RO7486967

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • For up to approximately 28 days

  • DrugPlacebo

    For up to approximately 28 days

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with adverse events (AEs)

    Time frame: Up to 45 Days

  2. The change in Columbia-Suicide Severity Rating Scale (C-SSRS) Scores from baseline

    Time frame: From Baseline to Up to 45 Days

Secondary outcomes

  1. Time to maximum concentration of RO7486967 in Plasma

    Time frame: Day 1, Day 15, and Day 28

  2. Maximum concentration (Cmax) of RO7486967 in Plasma

    Time frame: Day 1, Day 15, and Day 28

  3. Area under the curve (AUC) RO7486967 in Plasma

    Time frame: Day 1, Day 15, and Day 28

  4. Change from baseline in parametric bindings of [18F]-DPA-714 in different brain areas at Day 25 PET

    Time frame: From Baseline to Approximately Day 25

07

Study locations

17 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • CenExel Rocky Mountain Clinical Research, LLC
    Englewood, Colorado 80113, United States
  • Georgetown University
    Washington, District of Columbia 20007, United States
  • Advent Health Orlando
    Orlando, Florida 32804, United States
  • Quest Research Institute
    Farmington Hills, Michigan 48334, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • The Movement Disorder Clinic of Oklahoma
    Tulsa, Oklahoma 74136, United States
  • University Pennsylvania Hospital
    Philadelphia, Pennsylvania 19104, United States
  • Brain Research Center B.V
    Amsterdam, 1081 GN, Netherlands
  • UMC St Radboud
    Nijmegen, 6525 GA, Netherlands
  • Brain Research Center Zwolle
    Zwolle, 8025AZ, Netherlands
  • University of Exeter
    Exeter, EX4 4RN, United Kingdom
  • Barts Health NHS Trust
    London, E1 2ES, United Kingdom
  • Imperial College Healthcare NHS Trust; Charing Cross Hospital
    London, W6 8RF, United Kingdom
  • National Hospital for Neurology and Neurosurgery; Leonard Wolfson Experimental Neurology Centre CRF
    London, WC1N 3BG, United Kingdom
  • Campus for Ageing & Vitality; Clincal Ageing Research Unit
    Newcastle, NE4 5PL, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Jul 2024, 21 months.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's 21 months is above that.

Counting every sponsor, half of 204 studies reached it within 19 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2023
First posted
Jun 29, 2023
StartActual
Sep 22, 2022
Primary completionActual
Jul 18, 2024
CompletionActual
Jul 18, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05924243
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 29, 2023
Start date
Sep 22, 2022
Primary completion
Jul 18, 2024
Completion
Jul 18, 2024
Last update
Sep 19, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selnoflast

Start the discussion